NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

HRMY | NASDAQ

$40.39 $1.13 | 2.88%
SIGNAL:Signal available — unlock to view |2026-09-30 |F&G 50 |RSI 49.4

Company Overview:

Market Cap: $2.29B
Trailing PE: 13.1x
FWD PE *: 10.3x
Payout Ratio (TTM): —
52-Week Range: $25.52 - $43.49

* Forward PE is based on street estimates.

6.1 Year HRMY Performance Metrics:

Total Return (with DRIP): 9.1% (1.44% CAGR)
Total Return (no DRIP): 9.1% (1.44% CAGR)
Share Price: 9.1% (1.44% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $10,913
Total Return $ (with DRIP): $913
HRMY Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
HRMY Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

HRMY Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

HRMY - Revenue
HRMY Revenue CAGR:1Y: 30.32%2Y: 22.96%5Y: 28.76%10Y: 0.00%
HRMY - Earnings Per Share (EPS)
HRMY EPS CAGR:1Y: 88.24%2Y: 152.98%5Y: 39.77%10Y: 0.00%
HRMY - Net Income
HRMY Net Income CAGR:1Y: 89.64%2Y: 155.10%5Y: 39.82%10Y: 0.00%
HRMY - EBITDA
HRMY EBITDA CAGR:1Y: 72.66%2Y: 78.38%5Y: 29.54%10Y: 0.00%
HRMY - Free Cash Flow
HRMY Free Cash Flow CAGR:1Y: 16.53%2Y: 48.38%5Y: 38.91%10Y: 0.00%
HRMY - Free Cash Flow / Share
HRMY Free Cash Flow / Share CAGR:1Y: 15.71%2Y: 46.99%5Y: 38.46%10Y: 0.00%
HRMY - Operating Income
HRMY Operating Income CAGR:1Y: 85.38%2Y: 104.51%5Y: 30.82%10Y: 0.00%
HRMY - Gross Profit
HRMY Gross Profit CAGR:1Y: 22.02%2Y: 18.66%5Y: 26.51%10Y: 0.00%
HRMY - Shares Outstanding
HRMY Shares Outstanding CAGR:1Y: 0.59%2Y: 1.06%5Y: 0.06%10Y: 0.00%
HRMY - Share Buybacks
HRMY Share Buybacks CAGR:1Y: 0.00%2Y: 99.91%5Y: 0.00%10Y: 0.00%
HRMY - Stock-Based Comp
HRMY Stock-Based Comp CAGR:1Y: -18.51%2Y: -7.72%5Y: 19.65%10Y: 0.00%
HRMY - Expenses
HRMY Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
HRMY - Revenue by Region
HRMY Revenue CAGR:1Y: 30.32%2Y: 22.96%5Y: 28.76%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

HRMY - REVENUE: Actual + Estimates
HRMY Actual Revenue CAGR:1Y: 30.32%2Y: 22.96%5Y: 28.76%10Y: 0.00%
HRMY - EPS: Actual + Estimates
HRMY Actual EPS CAGR:1Y: 88.24%2Y: 152.98%5Y: 39.77%10Y: 0.00%
HRMY - NET INCOME: Actual + Estimates
HRMY Actual Net Income CAGR:1Y: 89.64%2Y: 155.10%5Y: 39.82%10Y: 0.00%
HRMY - EBITDA: Actual + Estimates
HRMY Actual EBITDA CAGR:1Y: 72.66%2Y: 78.38%5Y: 29.54%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

HRMY - Net Profit Margin
HRMY Net Profit Margin CAGR:1Y: 45.51%2Y: 107.43%5Y: 8.59%10Y: 0.00%
HRMY - Gross Profit Margin
HRMY Gross Profit Margin CAGR:1Y: -6.37%2Y: -3.49%5Y: -1.75%10Y: 0.00%
HRMY - Price to Earnings
HRMY Price to Earnings CAGR:1Y: -38.84%2Y: -57.09%5Y: -24.33%10Y: 0.00%
HRMY - Price To Sales Ratio
HRMY Price To Sales Ratio CAGR:1Y: -10.96%2Y: -10.19%5Y: -18.02%10Y: 0.00%
HRMY - Return on Capital Employed
HRMY Return on Capital Employed CAGR:1Y: 51.02%2Y: 61.67%5Y: 1.68%10Y: 0.00%
HRMY - Return on Invested Capital
HRMY Return on Invested Capital CAGR:1Y: 52.95%2Y: 99.49%5Y: -0.31%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for HRMY

Based on past 6.1-year performance, here are HRMY growth metrics:

Share price CAGR of +1.44%
Dividend CAGR of +0%

Using HRMY CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

HRMY (DRIP)HRMY - No DRIP
Current Price$40.39$40.39
Start Shares247.59247.59
Start Value$10,000$10,000
  
After 10 years:
Final Share Count247.59247.59
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$40.39$40.39
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - HRMY

NOTE: Above numbers are our estimate based on HRMY's Dividend and Price CAGR over past 6.1 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

Harmony Biosciences Holdings, Inc. (HRMY) had its IPO on 2020-08-19, and is traded on NASDAQ stock exchange.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

HRMY website: https://www.harmonybiosciences.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — HRMY

Value from:
Pay up to today
—
vs current price $40.39
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →